Glaucocalyxin A delays the progression of OA by inhibiting NF-κB and MAPK signaling pathways

Xin Hong,Xuqiang Liu,Bo Li,Shoujie Shi,Kai Xiao,Tiantian Xu,Yaoyang Nie,Min Dai,Meisong Zhu
DOI: https://doi.org/10.1186/s13018-024-04640-z
IF: 2.6
2024-03-20
Journal of Orthopaedic Surgery and Research
Abstract:Osteoarthritis (OA) is a common degenerative joint condition marked by inflammation and cartilage breakdown. Currently, there is a dearth of treatment medications that can clearly slow the course of OA. Glaucocalyxin A (GLA) is a diterpene chemical identified and extracted from Rabdosia japonica with antithrombotic, anticoagulant, anti-tumor, anti-inflammatory, anti-oxidant, and other pharmacological properties. Previous research has linked inflammation to abnormalities in the homeostasis of the extracellular matrix (ECM). Although GLA has been shown to have anti-inflammatory qualities, its effects on the progression of OA are unknown. As a result, the goal of this study was to see if GLA could slow the course of OA.
orthopedics
What problem does this paper attempt to address?